Zetagen Therapeutics Secures $12.9M Series B1 Funding

Why It Matters

The funding validates investor confidence in Zetagen’s novel delivery approach and provides resources to advance three breast‑cancer candidates, potentially reshaping treatment paradigms and creating a new market niche for intratumoral therapies.

Deal Summary

Zetagen Therapeutics announced the close of a $12.9 million Series B1 round, 100 % oversubscribed and led by JSTAR Capital Investments. The funding will support the development of its intratumoral breast cancer therapeutics platform.